Detalles de la búsqueda
1.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153538
2.
Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
Cancer
; 119(11): 1969-75, 2013 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23505007
3.
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
Oncologist
; 20(2): 224-6, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25568147
4.
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Lung Cancer
; 91: 70-2, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26464158
5.
Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Lung Cancer
; 96: 15-8, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27133743
6.
Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Lung Cancer
; 87(2): 207-9, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25558789
7.
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
Lung Cancer
; 88(3): 355-9, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25882777
8.
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Lung Cancer
; 88(2): 231-4, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736571
9.
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
Lung Cancer
; 88(3): 352-4, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25851827
10.
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
J Thorac Oncol
; 9(12): 1821-5, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25393796
11.
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
J Thorac Oncol
; 9(4): 549-53, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24736079
12.
Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.
J Thorac Oncol
; 6(12): 2135-7, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22088989
Resultados
1 -
12
de 12
1
Próxima >
>>